
Explore Cerebion Modulation in Multiple Myeloma Based on In Vitro Studies¹⁻⁵



IMiDs belong to the class of cereblon E3 ligase modulators. While they have a shared target with novel agents such as iberdomide and CC-92480, their downstream effects differ.


The safety and efficacy of the agents and/or uses under investigation have not been established. There is no guarantee that the agents will receive health authority approval or become commercially available in any country for the uses being investigated.





Role of Oncogenes in Myeloma Cell Activity

Based on In Vitro Studies



ligase complex

protein degradation⁶

Initiates ubiquitin-mediated

Transcription factors











Nucleus

Cytoplasm

Upregulation of oncogenes IRF4 and c-MYC in myeloma cells promotes myeloma cell proliferation¹³

+ Proteasome

IMiDs belong to the class of cereblon E3 ligase modulators. While they have a shared target with novel agents such as iberdomide and CC-92480, their downstream effects differ.

The safety and efficacy of the agents and/or uses under investigation have not been established. There is no guarantee that the agents will receive health authority approval or become commercially available in any country for the uses being investigated.


Bristol Myers Squibb

IMID* and CELMoD* are registered trademarks of Bristol-Myers Squibb Company. © 2021 Bristol-Myers Squibb Company. All rights reserved. VV-MED-01745 04/21



Cereblon Modulation Inside a Myeloma Cell

Based on In Vitro Studies



Bristol Myers Squibb

IMiD® and CELMoD® are registered trademarks of Bristol-Myers Squibb Company.


© 2021 Bristol-Myers Squibb Company, All rights reserved. VV-MED-01745 04/21

The safety and efficacy of the agents and/or uses under investigation have not been established. There is no guarantee that the agents will receive health authority approval or become commercially available in any country for the uses being investigated.



Cereblon Modulation Inside a Myeloma Cell

Based on In Vitro Studies




with novel agents such as iberdomide and CC-92480, their downstream effects differ.

The safety and efficacy of the agents and/or uses under investigation have not been established. There is no guarantee that the agents will receive health authority approval or become commercially available in any country for the uses being investigated.



T-Cell Activity in Multiple Myeloma

Based on In Vitro Studies



Initiates ubiquitin-mediated protein degradation⁶

Transcription factors





Cytoplasm

Nucleus

(+) IL-2

Ikaros and Aiolos repress IL-2 gene expression9

Proteasome

IMiDs belong to the class of cereblon E3 ligase modulators. While they have a shared target with novel agents such as iberdomide and CC-92480, their downstream effects differ.

The safety and efficacy of the agents and/or uses under investigation have not been established. There is no guarantee that the agents will receive health authority approval or become commercially available in any country for the uses being investigated.




IMiD® and CELMoD® are registered trademarks of Bristol-Myers Squibb Company.

© 2021 Bristol-Myers Squibb Company. All rights reserved. VV-MED-01745 04/21



Cereblon Modulation Inside a T Cell

Based on In Vitro Studies



Cereblon E3 ubiquitin

Initiates ubiquitin-mediated protein degradation⁶

ligase complex

Remove IMiD® Agents



Ikaros and Aiolos are





Preclinical studies have demonstrated that targeting Ikaros and Aiolos for degradation resulted in increased expression of *IL-2*. This led to an increase in the number and function of NK and T cells.^{5,10,16}

Proteasome

IMiDs belong to the class of cereblon E3 ligase modulators. While they have a shared target with novel agents such as iberdomide and CC-92480, their downstream effects differ.

The safety and efficacy of the agents and/or uses under investigation have not been established. There is no guarantee that the agents will receive health authority approval or become commercially available in any country for the uses being investigated.



IMID* and CELMoD* are registered trademarks of Bristol-Myers Squibb Company.

© 2021 Bristol-Myers Squibb Company, All rights reserved. VV-MED-01745 04/21


Cytoplasm

Nucleus




Cereblon Modulation Inside a T Cell


Based on In Vitro Studies







Cerebion E3 ubiquitin ligase complex initiates ubiquitin-mediated protein degradations



More-potent co-opting of cereblon with CELMoD agents²⁰

Remove IMID®





_

Nucleus

Cytoplasm

Preclinical studies have demonstrated that targeting Ikaros and Aiolos for degradation resulted in increased expression of *IL-2*. This led to an increase in the number and function of NK and T cells, 5,10,16

Proteasome



Enhanced IL-2 expression and immune stimulatory effect with CELMoD agents^{21, 22}

IMiDs belong to the class of cerebion E3 ligase modulators. While they have a shared target with novel agents such as iberdomide and CC-92480, their downstream effects differ.

The safety and efficacy of the agents and/or uses under investigation have not been established. There is no guarantee that the agents will receive health authority approval or become commercially available in any country for the uses being investigated.

IMiD® and CELMoD® are registered trademarks of Bristol-Myers Squibb Company.
© 2021 Bristol-Myers Squibb Company. All rights reserved. VV-MED-01745 04/21